Welcome to our dedicated page for Novanta SEC filings (Ticker: NOVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Novanta Inc. filings document the company's operating results, governance matters and capital structure as an operating technology supplier to medical and advanced technology equipment manufacturers. Form 8-K reports furnish earnings releases and financial guidance updates, report board and committee changes, and disclose authorizations for common-share repurchases.
The company's filings also include capital-markets disclosures for Novanta's 6.50% tangible equity units, including underwriting arrangements, unit issuance and related registration-statement references. The definitive proxy statement covers shareholder voting matters, board governance, executive compensation, equity awards and pay-versus-performance information for the company's annual meeting process.
Novanta Inc. entered into a Securities Purchase Agreement for a private placement of common shares expected to raise gross proceeds of approximately $300 million. Institutional and other accredited investors agreed to buy 2,142,857 common shares at $140.00 per share, with closing targeted for June 11, 2026, subject to customary conditions.
The shares are being sold in an unregistered transaction under Section 4(a)(2) of the Securities Act, and Novanta agreed in a Registration Rights Agreement to register their resale after closing. As of June 8, 2026, Novanta had 35,613,303 common shares outstanding; including a minimum 4,717,185 shares issuable under Tangible Equity Units, there would be 42,473,345 common shares outstanding or issuable following the closing.
Novanta Inc. entered into a Securities Purchase Agreement for a private placement of common shares expected to raise gross proceeds of approximately $300 million. Institutional and other accredited investors agreed to buy 2,142,857 common shares at $140.00 per share, with closing targeted for June 11, 2026, subject to customary conditions.
The shares are being sold in an unregistered transaction under Section 4(a)(2) of the Securities Act, and Novanta agreed in a Registration Rights Agreement to register their resale after closing. As of June 8, 2026, Novanta had 35,613,303 common shares outstanding; including a minimum 4,717,185 shares issuable under Tangible Equity Units, there would be 42,473,345 common shares outstanding or issuable following the closing.
Novanta Inc. is making a major move into minimally invasive surgical consumables by agreeing to acquire Riverpoint Medical for an upfront cash payment of $1.2 billion, plus a $250 million milestone payment expected in early 2027.
Riverpoint generates about $150 million in revenue with >50% adjusted gross margins, ~40% adjusted EBITDA margins and a 12%–15% organic growth outlook, roughly twice Novanta’s current growth rate. Novanta expects the deal to double recurring medical consumables revenue to roughly $300 million and increase medical end-market exposure to about 60% of total sales.
The transaction is expected to be immediately accretive to Novanta’s Adjusted Diluted EPS in 2026, and in 2027 accretive to revenue growth, adjusted margins, earnings and operating cash flow. It will be funded with cash on hand, existing credit facilities and a completed $300 million equity raise, with a targeted net leverage ratio of about 2.7x at closing and below 2.3x by year-end 2027.
Novanta Inc. is making a major move into minimally invasive surgical consumables by agreeing to acquire Riverpoint Medical for an upfront cash payment of $1.2 billion, plus a $250 million milestone payment expected in early 2027.
Riverpoint generates about $150 million in revenue with >50% adjusted gross margins, ~40% adjusted EBITDA margins and a 12%–15% organic growth outlook, roughly twice Novanta’s current growth rate. Novanta expects the deal to double recurring medical consumables revenue to roughly $300 million and increase medical end-market exposure to about 60% of total sales.
The transaction is expected to be immediately accretive to Novanta’s Adjusted Diluted EPS in 2026, and in 2027 accretive to revenue growth, adjusted margins, earnings and operating cash flow. It will be funded with cash on hand, existing credit facilities and a completed $300 million equity raise, with a targeted net leverage ratio of about 2.7x at closing and below 2.3x by year-end 2027.
Novanta Inc. director and CEO Matthijs Glastra reported open-market sales of 6,500 shares of common stock on June 2, 2026. The shares were sold in multiple transactions at prices ranging from $164.61 to $171.28, according to the Form 4 data.
The filing shows Glastra now directly owns 42,723 Novanta shares and indirectly holds 54,382 shares through the Matthijs Glastra 2021 Irrevocable Trust. The sales were executed under a pre-established Rule 10b5-1 trading plan adopted on September 11, 2025, indicating they were pre-arranged rather than discretionary trades.
Novanta, Inc. submitted an amendment to a Form 144 that lists notices of proposed sales of Common stock. The filing names Merrill Private Wealth Management as an intermediary and records multiple sale entries of 6,500 shares and one entry of 7,500 shares on specific dates in 2026.
Novanta, Inc. (NOVT) submitted a Form 144 notice showing holder/sponsor activity for Common Stock. The filing lists 7,500 shares associated with Merrill Private Wealth Management and multiple restricted stock unit lots (3,618; 1,744; 1,870; 268) with grant dates between 02/26/2017 and 02/25/2020. The excerpt also lists recent reported sales by Matthijs Glastra: 7,500 shares on 02/10/2026, 6,500 shares on 03/02/2026, 6,500 shares on 04/17/2026, and 6,500 shares on 05/05/2026.
Novanta Inc. reported the results of its 2026 annual meeting of shareholders. A total of 33,371,777 common shares were represented, equal to 93.71% of outstanding shares as of April 14, 2026. All nine director nominees received strong majority support and were elected for terms ending at the 2027 annual meeting.
Shareholders also approved, on an advisory basis, the Company’s executive compensation and ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm through the next annual meeting.
Novanta Inc. amended its main credit agreement to add $200.0 million in delayed draw term loan commitments. This new facility can be drawn at the company’s option for up to six months after May 15, 2026, giving additional funding flexibility.
The Delayed Draw Term Loans will mature on June 27, 2030 and bear interest at either the Base Rate plus 0.00%-0.75% or SOFR/SONIA/EURIBOR plus 1.00%-1.75%, depending on Novanta’s consolidated leverage ratio. The loans amortize quarterly starting with the fiscal quarter ending September 25, 2026, initially at 0.625% of outstanding U.S. dollar term loans, increasing to at least 1.25% from late June 2027. Novanta will also pay a commitment fee on undrawn amounts, and its incremental term loan and revolver capacity are reset from the amendment date.
Novanta Inc. amended its main credit agreement to add $200.0 million in delayed draw term loan commitments. This new facility can be drawn at the company’s option for up to six months after May 15, 2026, giving additional funding flexibility.
The Delayed Draw Term Loans will mature on June 27, 2030 and bear interest at either the Base Rate plus 0.00%-0.75% or SOFR/SONIA/EURIBOR plus 1.00%-1.75%, depending on Novanta’s consolidated leverage ratio. The loans amortize quarterly starting with the fiscal quarter ending September 25, 2026, initially at 0.625% of outstanding U.S. dollar term loans, increasing to at least 1.25% from late June 2027. Novanta will also pay a commitment fee on undrawn amounts, and its incremental term loan and revolver capacity are reset from the amendment date.
NOVANTA INC Chief Executive Officer Matthijs Glastra reported selling common stock in a pre-planned transaction. On May 12, 2026, he completed open-market sales totaling 7,500 shares at prices around $150–$151.34 per share under a pre-established Rule 10b5-1 trading plan.
Following these sales, he directly held 42,761 shares of Novanta common stock and indirectly held 54,382 shares through the Matthijs Glastra 2021 Irrevocable Trust. One sale at a weighted-average price of $151.34 was executed in multiple trades between $151.06 and $151.51.
Novanta, Inc. submitted Rule 144 notices reporting proposed resale of common stock by an affiliate and recent open-market sales. The filing lists a proposed sale quantity of 7,500 shares tied to Merrill Private Wealth Management and shows multiple previously reported sales by Matthijs Glastra totaling 26,000 shares across four transactions dated 02/10/2026, 03/02/2026, 04/17/2026, and 05/05/2026.
The excerpt also itemizes Restricted Stock Units granted on 02/25/2020 (3,618 RSUs), 02/24/2020 (1,744 RSUs), 03/03/2017 (1,870 RSUs) and 02/26/2017 (268 RSUs). Dollar proceeds are shown for each recent sale in the table (for example, $1,087,500 for the 02/10/2026 sale).
Novanta Inc. reported solid Q1 2026 revenue growth while earnings were roughly flat. Revenue rose to $257.7M from $233.4M, driven by both Automation Enabling Technologies and Medical Solutions. Automation Enabling Technologies generated $131.2M and Medical Solutions $126.5M of revenue.
Net income was stable at $21.1M versus $21.2M a year earlier, with diluted EPS slipping to $0.51 from $0.59 as the share count increased. Operating income declined to $27.5M from $32.4M as selling, general and administrative expenses and restructuring and acquisition costs increased.
Operating cash flow strengthened to $51.6M from $31.7M, supporting a cash balance of $388.8M and total debt of $241.4M. The company continued buybacks, repurchasing 159 thousand shares for $18.6M, and ended the quarter with 35.6M common shares outstanding.